{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:35:40Z","timestamp":1772580940234,"version":"3.50.1"},"reference-count":35,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: Pegvisomant (PEG) therapy has been associated with drug-induced liver dysfunction in acromegalic patients. The mechanism of its toxicity remains unknown.<\/jats:p>\n                  <jats:p>Objective: The primary objective was to determine whether or not the UGT1A1*28 polymorphism associated with Gilbert\u2019s syndrome influences the development of liver dysfunction during PEG treatment.<\/jats:p>\n                  <jats:p>Design and Setting: A cross-sectional study was conducted in four Spanish university hospitals.<\/jats:p>\n                  <jats:p>Patients: Thirty-six acromegalic patients with active disease, resistant to somatostatin analogs, participated.<\/jats:p>\n                  <jats:p>Results: The prevalence of the UGT1A1*28 homozygous and heterozygous genotypes in acromegalic patients was 14 and 44%, respectively. Ten patients (28%) developed liver function test (LFT) abnormalities. There was a tendency for more frequent liver function abnormalities in males (70% males vs. 30% females, P = 0.058). Carriers of the UGT1A1*28 polymorphism had a higher incidence of LFT abnormalities than the UGT1A1 wild type (43% carriers vs. 7% wild type, P = 0.024). This difference persisted when adjusted in an all-factors multiple regression analysis [coefficient of determination (R2) = 0.463; P = 0.008] for age, gender, alcohol consumption, and UGT1A1*28 polymorphism. A stepwise multivariate likelihood binary logistic regression analysis (R2 = 0.40; P = 0.003) identified male gender (\u03b2 = 7.21; P = 0.033) and UGT1A1*28 polymorphism (\u03b2 = 14.1; P = 0.028) as the only significant predictors for the development of LFT abnormalities.<\/jats:p>\n                  <jats:p>Conclusions: The UGT1A1*28 genotype and male gender predict an increased incidence of LFT abnormalities during PEG therapy in acromegaly.<\/jats:p>","DOI":"10.1210\/jc.2009-2547","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T22:01:25Z","timestamp":1267826485000},"page":"2147-2154","source":"Crossref","is-referenced-by-count":37,"title":["Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert\u2019s Syndrome"],"prefix":"10.1210","volume":"95","author":[{"given":"Ignacio","family":"Bernabeu","sequence":"first","affiliation":[{"name":"Endocrinology Division (I.B., E.F.-R., F.F.C.), Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo\u0301nica","family":"Marazuela","sequence":"additional","affiliation":[{"name":"Endocrinology Division (M.M., M.L.-R., A.-E.P.), Hospital Universitario de La Princesa, Universidad Auto\u0301noma de Madrid, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toma\u0301s","family":"Lucas","sequence":"additional","affiliation":[{"name":"Endocrinology Division (T.L.), Hospital Puerta de Hierro-Majadahonda, Universidad Auto\u0301noma de Madrid, 28222 Majadahonda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Loidi","sequence":"additional","affiliation":[{"name":"Fundacio\u0301n Publica Galega de Medicina Xeno\u0301mica (Unidad de Medicina Molecular) (L.L., C.Q.), Complejo Hospitalario Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alvarez-Escola\u0301","sequence":"additional","affiliation":[{"name":"Endocrinology Division (C.A.-E.), Hospital Universitario La Paz, Universidad Auto\u0301noma de Madrid, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Luque-Rami\u0301rez","sequence":"additional","affiliation":[{"name":"Endocrinology Division (M.M., M.L.-R., A.-E.P.), Hospital Universitario de La Princesa, Universidad Auto\u0301noma de Madrid, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Fernandez-Rodriguez","sequence":"additional","affiliation":[{"name":"Endocrinology Division (I.B., E.F.-R., F.F.C.), Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia-Elisa","family":"Paniagua","sequence":"additional","affiliation":[{"name":"Endocrinology Division (M.M., M.L.-R., A.-E.P.), Hospital Universitario de La Princesa, Universidad Auto\u0301noma de Madrid, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celsa","family":"Quinteiro","sequence":"additional","affiliation":[{"name":"Fundacio\u0301n Publica Galega de Medicina Xeno\u0301mica (Unidad de Medicina Molecular) (L.L., C.Q.), Complejo Hospitalario Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe F.","family":"Casanueva","sequence":"additional","affiliation":[{"name":"Endocrinology Division (I.B., E.F.-R., F.F.C.), Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Fisiopatologi\u0301a Obesidad y Nutricio\u0301n (F.F.C.), Instituto Salud Carlos III, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071614131608100_R1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"Verma","year":"2009","journal-title":"Gut"},{"key":"2020071614131608100_R2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00204-008-0314-x","article-title":"Family 1 uridine-5\u2032-diphosphate glucuronosyltransferases (UGT1A): from Gilbert\u2019s syndrome to genetic organization and variability","volume":"82","author":"Strassburg","year":"2008","journal-title":"Arch Toxicol"},{"key":"2020071614131608100_R3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/14622416.9.6.703","article-title":"Pharmacogenetics of Gilbert\u2019s syndrome","volume":"9","author":"Strassburg","year":"2008","journal-title":"Pharmacogenomics"},{"key":"2020071614131608100_R4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1440-1746.1999.01984.x","article-title":"Molecular genetic basis of Gilbert\u2019s syndrome","volume":"14","author":"Burchell","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"2020071614131608100_R5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"2020071614131608100_R6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071614131608100_R7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/mol.62.3.446","article-title":"Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity","volume":"62","author":"Tukey","year":"2002","journal-title":"Mol Pharmacol"},{"key":"2020071614131608100_R8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/hep.21361","article-title":"Gilbert\u2019s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype","volume":"44","author":"Lankisch","year":"2006","journal-title":"Hepatology"},{"key":"2020071614131608100_R9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0006-2952(03)00074-1","article-title":"Frequent co-occurrence of the TATA box mutation associated with Gilbert\u2019s syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians","volume":"65","author":"Ko\u0308hle","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"2020071614131608100_R10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"2020071614131608100_R11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071614131608100_R12","first-page":"1716","article-title":"Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer","volume":"86","author":"Ross","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614131608100_R13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/ncpendmet0831","article-title":"Long-term effects of pegvisomant in patients with acromegaly","volume":"6","author":"Hodish","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071614131608100_R14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/eje.1.02079","article-title":"Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis","volume":"154","author":"Biering","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2020071614131608100_R15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","article-title":"The German ACROSTUDY: past and present","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1530\/eje.1.02160","article-title":"Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant","volume":"154","author":"Feenstra","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R18","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614131608100_R19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R20","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"key":"2020071614131608100_R21","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614131608100_R22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/EJE-08-0705","article-title":"Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy","volume":"160","author":"Marazuela","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1530\/EJE-09-0040","article-title":"Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert\u2019s syndrome","volume":"160","author":"Bernabeu","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071614131608100_R24","article-title":"Self-limited acute hepatotoxicity caused by pegvisomant","author":"Soto Moreno","year":"2009","journal-title":"Pituitary"},{"key":"2020071614131608100_R25","first-page":"526","article-title":"Criteria for cure of acromegaly: a consensus statement","volume":"85","author":"Giustina","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614131608100_R26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/jc.2009-1630","article-title":"The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly","volume":"95","author":"Bernabeu","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614131608100_R27","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3748\/wjg.15.2817","article-title":"Drug-induced liver injury: is it somehow foreseeable?","volume":"15","author":"Tarantino","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2020071614131608100_R28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2007.06.001","article-title":"Mechanisms of drug-induced liver disease","volume":"11","author":"Gunawan","year":"2007","journal-title":"Clin Liver Dis"},{"key":"2020071614131608100_R29","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr Med Chem"},{"key":"2020071614131608100_R30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00008571-200212000-00006","article-title":"Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups","volume":"12","author":"Innocenti","year":"2002","journal-title":"Pharmacogenetics"},{"key":"2020071614131608100_R31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(02)00306-9","article-title":"Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert\u2019s syndrome","volume":"38","author":"Peters","year":"2003","journal-title":"J Hepatol"},{"key":"2020071614131608100_R32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2265.2007.02811.x","article-title":"Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems","volume":"66","author":"Paisley","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614131608100_R33","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.22177","article-title":"Acute liver failure: summary of a workshop","volume":"47","author":"Lee","year":"2008","journal-title":"Hepatology"},{"key":"2020071614131608100_R34","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.21424","article-title":"Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry","volume":"44","author":"Andrade","year":"2006","journal-title":"Hepatology"},{"key":"2020071614131608100_R35","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","article-title":"ACROSTUDY: the first 5 years","author":"Trainer","year":"2009","journal-title":"Eur J Endocrinol 161: S1,"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/5\/2147\/9067432\/jcem2147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/5\/2147\/9067432\/jcem2147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:40:37Z","timestamp":1594935637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/5\/2147\/2596750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-2547","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2969956.2642054","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,1]]}}}